Skip to main content

Table 1 Patient disposition: long-term analysis

From: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Disposition, n (%) mBCC laBCC All patients
(n = 33) (n = 71) (N = 104)
On treatment 1 (3.0) 7 (9.9) 8 (7.7)
Discontinued treatment 32 (97.7) 64 (90.1) 96 (92.3)
Main reason
 AE 5 (15.2) 17 (23.9) 22 (21.2)
 Death 1 (3.0) 2 (2.8) 3 (2.9)
 Lost to follow-up 1 (3.0) 2 (2.8) 3 (2.9)
 Physician decision 3 (9.1) 7 (9.9) 10 (9.8)
 Patient decision 4 (12.1) 23 (32.4) 27 (26.0)
 Disease progression 17 (51.5) 12 (16.9) 29 (27.9)
 Other 1 (3.0) 1 (1.4) 2 (1.9)
  1. AE adverse event, laBCC locally advanced basal cell carcinoma, mBCC metastatic basal cell carcinoma